American Oncology Network Expands Radiology and Imaging Program with New Physician Leaders and Advances Radiopharmaceutical Therapies

American Oncology Network (AON) says it has grown its radioligand therapy program to nine active centers (since its first 2023 site) and has five more sites in development. AON also expanded radiology/radiation oncology physician leadership with two appointments (Robert J. McDonald, MD as radiology medical director; Jason Berilgen, MD as radiation oncology medical director) to broaden PET/CT interpretation and image-guided radiotherapy capabilities. The update is incremental and points to continued expansion of access to targeted radiopharmaceutical therapies in community settings.

Analysis

This is more a proof-of-platform than a near-term earnings event. The economic value is not in the press-release count of sites; it is in whether AONC can convert those locations into sustained, reimbursable throughput with enough case density to offset the fixed cost of nuclear medicine staffing, protocolization, and compliance. In that sense, the first-order beneficiary is AONC, but the more durable beneficiaries are the upstream tools and tracer ecosystem that gain from more PET/imaging pull-through and from the normalization of radioligand pathways.

The key second-order effect is competitive leakage away from hospital outpatient oncology and academic centers toward lower-cost community settings. That shift can pressure higher-cost sites over a 6-18 month horizon, but only if payers continue to steer volume and prior authorization remains manageable. The near-term risk is that capacity gets built faster than utilization, which would make the expansion margin-dilutive before it becomes margin-accretive.

The contrarian issue is that investors often extrapolate TAM from center openings while underweighting execution friction: isotope supply, trained staff, reimbursement timing, and physician workflow integration. If next-quarter data do not show higher case mix or better reimbursement-adjusted margin, the market should fade the narrative rather than reward the rollout. In other words, the catalyst is not more announcements; it is evidence that the new centers are filling and monetizing.

Key Decisions for Investors

• No immediate chase in AONC; treat this as a watch item until the next print shows center utilization, reimbursement mix, and margin contribution. If those metrics fail to inflect, this is likely headline noise rather than a tradable earnings lever.
• Long LNTH on weakness over the next 1-3 months as the cleaner public-market proxy for rising PET/radiopharma adoption. Risk/reward improves if imaging volumes and guidance stabilize; thesis is falsified by slower tracer growth or pricing pressure.
• Long NVS as a 6-18 month secular radioligand adoption trade if you want direct exposure to therapeutic penetration. Reduce or exit if management commentary points to supply constraints, reimbursement friction, or slower-than-expected throughput.
• If AONC is liquid enough, consider a small tactical long only after a pullback, sized as event-driven optionality rather than a core position. Use the next earnings release as the key checkpoint; if there is no evidence of operating leverage, cut the trade.